When high is low: raising low levels of high-density lipoprotein cholesterol

Area of Science:

• Cardiology
• Lipidology
• Preventive Medicine

Background:

• Low serum high-density lipoprotein cholesterol (HDL-C) is prevalent and a key independent risk factor for cardiovascular morbidity and mortality.
• HDL cholesterol plays a crucial role in modulating atherogenesis, but its complex functions and antiatherogenic mechanisms require further elucidation.
• A well-established inverse relationship exists between HDL-C levels and cardiovascular risk, with higher levels demonstrating vasculoprotective effects.

Purpose of the Study:

• To discuss currently available therapeutic strategies for increasing suboptimal serum HDL-C levels.
• To highlight the importance of augmenting HDL functionality alongside raising HDL-C levels.
• To provide an overview of established treatments for managing low HDL-C.

Main Methods:

• Review of existing literature on HDL-C metabolism and cardiovascular disease.
• Analysis of clinical trial data and epidemiological studies on HDL-C.
• Discussion of currently approved and utilized therapies for dyslipidemia.

Main Results:

• Low HDL-C is a significant predictor of cardiovascular events including myocardial infarction and stroke.
• Epidemiological and clinical data consistently support the vasculoprotective role of higher HDL-C levels.
• While novel approaches are under investigation, existing therapies can be employed to address low HDL-C.

Conclusions:

• Managing low HDL-C levels is critical for cardiovascular risk reduction.
• Current therapeutic options focus on raising HDL-C and enhancing its function.
• Further research into HDL's complex mechanisms may unlock new treatment strategies.